Список литературы

1. Boothroyd C., Karia S., Andreadis N., Rombauts L., Johnson N., Chapman M. Consensus statement on prevention and detection of ovarian hyperstimulation syndrome. Aust New Zeal J Obstet Gynaecol. 2015; 55(6): 523 - 34.

2. Pfeifer S., Butts S., Dumesic D., Fossum G., Gracia C., La Barbera A., et al. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016 Dec; 106(7): 1634 - 47.

3. Tan B.K., Mathur R. Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee. Hum Fertil (Camb). 2013 Sep; 16(3): 151 - 9.

4. Carter R., Petrie K., Sadighi A., Skene H. Ovarian hyperstimulation syndrome on the acute medical unit: a problem-based review. Acute Med. 2015; 14(1): 21 - 7.

5. Namavar Jahromi B., Parsanezhad M.E., Shomali Z., Bakhshai P., Alborzi M., Moin Vaziri N., et al. Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. Iran J Med Sci. 2018 May; 43(3): 248 - 60.

6. Назаренко Т.А., Корнеева И.Е., Сароян Т.Т., Веряева Н.А. Спонтанный синдром гиперстимуляции яичников при одноплодной беременности. Проблемы репродукции. 2009; 15(1): 72 - 5.

7. Vasseur C., Rodien P., Beau I., Desroches A., , de Poncheville L., et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med [Internet]. 2003; 349(8): 753 - 9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12930927

8. Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril [Internet]. 2016; 106(7): 1634 - 47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27678032

9. Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. RCOG Green-top Guideline No. 37a April 2015.40 p.

10. Nelson S.M. Prevention and management of ovarian hyperstimulation syndrome. Thromb Res. 2017 Mar; 151 Suppl: S61 - 4.

11. Corbett S., Shmorgun D., Claman P., REPRODUCTIVE ENDOCRINOLOGY INFERTILITY COMMITTEE, SPECIAL CONTRIBUTOR. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can. 2014 Nov; 36(11): 1024 - 33.

12. Ironside E.C., Hotchen A.J. Ovarian hyperstimulation syndrome, the master of disguise? Case Rep Emerg Med. 2015; 2015: 510815.

13. Gibreel A., Maheshwari A., Bhattacharya S. Clomiphene citrate in combination with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane database Syst Rev. 2012; 11: CD008528.

14. Daelemans C., Smits G., de Maertelaer V., Costagliola S., Englert Y., Vassart G., et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab [Internet]. 2004; 89(12): 6310 - 5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15579795

15. Topdagi Yilmaz E.P., Yapca O.E., Topdagi Y.E., Kaya Topdagi S., Kumtepe Y. Spontaneous Ovarian Hyperstimulation Syndrome with FSH Receptor Gene Mutation: Two Rare Case Reports. Case Rep Obstet Gynecol. 2018 Oct; 2018: 1 - 5.

16. Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009 Jul; 19(1): 14 - 27.

17. Stouffs K., Daelemans S., Santos-Ribeiro S., Seneca S., Gheldof A., , et al. Rare genetic variants potentially involved in ovarian hyperstimulation syndrome. J Assist Reprod Genet. 2019 Mar; 36(3): 491 - 7.

18. Petrenko A.P., Castelo-Branco C., Marshalov D.V., Kuligin A.V., Shifman E.M., Nesnova E.S. Assessing the Usefulness of Severity Markers in Women with Ovarian Hyperstimulation Syndrome. Reprod Sci [Internet]. 2021 Apr 15; 28(4): 1041 - 8. Available from: http://link.springer.com/10.1007/s43032-020-00339-8

19. Lamazou F., Legouez A., Letouzey V., Grynberg M., Deffieux X., Trichot C., et al. [Ovarian hyperstimulation syndrome: pathophysiology, risk factors, prevention, diagnosis and treatment]. J Gynecol Obstet Biol Reprod (Paris). 2011 Nov; 40(7): 593 - 611.

20. Wei L-H, Chou C-H, Chen M-W, Rose-John S., Kuo M-L, Chen S-U, et al. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. J Clin Endocrinol Metab. 2013 Mar; 98(3): E472 - 84.

21. Kirkpatrick A.W., Roberts D.J., De Waele J., Jaeschke R., Malbrain MLNG, De Keulenaer B., et al. Intra-abdominal hypertension and the abdominal compartment syndrome: Updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013; 39(7): 1190 - 206.

22. Maslovitz S., Jaffa A., Eytan O., Wolman I., Many A., Lessing J.B., et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol. 2004 Aug; 104(2): 321 - 6.

23. Budev M.M., Arroliga A.C., Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med [Internet]. 2005; 33(10 Suppl): S301 - 6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16215351

24. Timmons D., Montrief T., Koyfman A., Long B. Ovarian hyperstimulation syndrome: A review for emergency clinicians. Am J Emerg Med. 2019; 37(8): 1577 - 84.

25. Сухих Г.Т., Сароян Т.Т. КИ. Иммунные аспекты патофизиологии синдрома гиперстимуляции яичников. Акушерство и гинекология. 2009; (3): 3 - 6.: 3 - 6.

26. Papanikolaou E.G., Pozzobon C., Kolibianakis E.M., Camus M., Tournaye H., Fatemi H.M., et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril [Internet]. 2006 Jan; 85(1): 112 - 20. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028205034369

27. Toftager M., Bogstad J., Bryndorf T., , , Holland T., et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod [Internet]. 2016 Jun; 31(6): 1253 - 64. Available from: https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/dew051

28. Ioannidou P.G., Bosdou J.K., Lainas G.T., Lainas T.G., Grimbizis G.F., Kolibianakis E.M. How frequent is severe ovarian hyperstimulation syndrome after GnRH agonist triggering in high-risk women? A systematic review and meta-analysis. Reprod Biomed Online [Internet]. 2021 Mar; 42(3): 635 - 50. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1472648320306246

29. Российская Ассоциация Репродукции Человека. Регистр ВРТ. Отчет за 2018 год. Санкт-Петербург. 2020. 80 p.

30. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Hyperstimulation Syndrome. Green-top Guideline No. 5. February 2016. 22 p.

31. Grossman L.C., Michalakis K.G., Browne H., Payson M.D., Segars J.H. The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. Fertil Steril. 2010 Sep; 94(4): 1392 - 8.

32. Veisi F., Zangeneh M., Malekkhosravi S., Rezavand N. Abdominal Compartment Syndrome Due to OHSS. J Obstet Gynaecol India. 2013 Oct; 63(5): 350 - 3.

33. Makino H., Furui T., Shiga T., Takenaka M., Terazawa K., Morishige K-I. Management of ovarian hyperstimulation syndrome with abdominal compartment syndrome, based on intravesical pressure measurement. Reprod Med Biol. 2017; 16(1): 72 - 6.

34. Назаренко Т.А., Корнеева И.Е., Аксененко А.А., Соколова М.Ю. Нарушение функции печени у пациентки с синдромом гиперстимуляции яичников. Проблемы репродукции. 2009; 15(3): 70 - 3.

35. Abramov Y., Elchalal U., Schenker J.G. Febrile morbidity in severe and critical ovarian hyperstimulation syndrome: a multicentre study. Hum Reprod [Internet]. 1998; 13(11): 3128 - 31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9853869

36. Веряева Н.А., Корнеева Н.Е., Анкирская А.С., Королева Т.Е. Оценка роли микробного фактора и диагностической ценности теста на прокальцитонин при синдроме гиперстимуляции яичников. Проблемы репродукции. 2009; 15(3): 35 - 9.

37. Nelson S.M. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thromb Res [Internet]. 2013; 131 Supph S1 - 3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23452730

38. , Jovanovic S., Albers A.E. [Jugular vein thrombosis caused by hypercoagulability following in-vitro fertilization-activated protein C resistance and immobilization]. HNO [Internet]. 2013; 61(3): 250 - 5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22532279

39. Mor Y.S., Schenker J.G. Ovarian hyperstimulation syndrome and thrombotic events. Am J Reprod Immunol. 2014 Dec; 72(6): 541 - 8.

40. , Rova K., Hellgren M., Hjertberg R., Nord E., Thurn L., et al. Thromboembolism and in vitro fertilization - a systematic review. Acta Obstet Gynecol Scand [Internet]. 2017; 96(9): 1045 - 52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28382684

41. Grandone E., Di Micco P.P., Villani M., Colaizzo D., , Del Toro J., et al. Venous Thromboembolism in Women Undergoing Assisted Reproductive Technologies: Data from the RIETE Registry. Thromb Haemost. 2018 Nov; 118(11): 1962 - 8.

42. Chan W.S. The "ART" of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol [Internet]. 2009; 21(3): 207 - 18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19276806

43. Gerris J., Delvigne A., Olivennes F. Ovarian Hyperstimulation Syndrome. CRC Press; 2006. 320 p.

44. Kwik M., Karia S., Boothroyd C. RANZCOG CREI Consensus Statement on treatment of Ovarian Hyperstimulation Syndrome. Aust N Z J Obstet Gynaecol [Internet]. 2015; 55(5): 413 - 9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26279582

45. Сароян Т.Т., Корнеева Н.Е. Тактика ведения индуцированной беременности, наступившей на фоне тяжелого течения синдрома гиперстимуляции яичников. Акушерство и гинекология. 2011; (8): 107 - 11.

46. Корнеева И.Е., Веряева Н.А. Комплексная терапия при синдроме гиперстимуляции яичников. Врач. 2006; (9): 54 - 5.

47. Синдром гиперстимуляции яичников. Клинические рекомендации 2019 г.

48. Lheureux O., Preiser J-C. Role of Nutrition Support in Inflammatory Conditions. Nutr Clin Pract. 2017 Jun; 32(3): 310 - 7.

49. "Методические рекомендации. Энтеральное питание в лечении хирургических и терапевтических больных" (утв. Минздравсоцразвития России 08.12.2006 N 6530-РХ).

50. Reintam Blaser A., Starkopf J., Alhazzani W., Berger M.M., Casaer M.P., Deane A.M., et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med. 2017 Mar; 43(3): 380 - 98.

51. Weimann A., Braga M., Carli F., Higashiguchi T., , Klek S., et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017; 36(3): 623 - 50.

52. Soni N. British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients (GIFTASUP): Cassandra's view. Anaesthesia [Internet]. 2009; 64(3): 235 - 8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19302633

53. Shmorgun D., Claman P. No-268-The Diagnosis and Management of Ovarian Hyperstimulation Syndrome. J Obstet Gynaecol Canada [Internet]. 2017 Nov; 39(11): e479 - 86. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1701216317309325

54. Tseng C-H, Chen T-T, Wu M-Y, Chan M-C, Shih M-C, Tu Y-K. Resuscitation fluid types in sepsis, surgical, and trauma patients: a systematic review and sequential network meta-analyses. Crit Care [Internet]. 2020 Dec 14; 24(1): 693. Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03419-y

55. Noonpradej S., Akaraborworn O. Intravenous Fluid of Choice in Major Abdominal Surgery: A Systematic Review. Crit Care Res Pract [Internet]. 2020 Aug 3; 2020: 1 - 19. Available from: https://www.hindawi.com/journals/ccrp/2020/2170828/

56. Tyagi A., Maitra S., Bhattacharjee S. Comparison of colloid and crystalloid using goal-directed fluid therapy protocol in non-cardiac surgery: a meta-analysis of randomized controlled trials. J Anesth [Internet]. 2020 Dec 27; 34(6): 865 - 75. Available from: http://link.springer.com/10.1007/s00540-020-02832-5

57. Zwager C.L., Tuinman P.R., de Grooth H-J, Kooter J., Ket H., Fleuren L.M., et al. Why physiology will continue to guide the choice between balanced crystalloids and normal saline: a systematic review and meta-analysis. Crit Care [Internet]. 2019 Dec 21; 23(1): 366. Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2658-4

58. Lincoln S.R., Opsahl M.S., Blauer K.L., Black S.H., Schulman J.D. Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization. J Assist Reprod Genet. 2002 Apr; 19(4): 159 - 63.

59. Маршалов Д.В., Садов И.А., Петренко А.П., Шифман Е.М., Салюков Р.Р. БМ. Влияние внутрибрюшной гипертензии на исходы синдрома гиперстимуляции яичников. Анестезиология и реаниматология. Акушерство и гинекология. 2013; (6): 42 - 7.

60. Youssef M.A., Mourad S. Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane database Syst Rev. 2016; (8): CD001302.

61. Chian R.C., Uzelac P.S., Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril. 2013; 99(5): 1173 - 81.

62. Gamzu R., Almog B., Levin Y., Avni A., Lessing J.B., Baram A. Efficacy of hydroxyethyl starch and haemaccel for the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril [Internet]. 2002; 77(6): 1302 - 3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12057749

63. Afshari A., Ageno W., Ahmed A., Duranteau J., Faraoni D., Kozek-Langenecker S., et al. European Guidelines on perioperative venous thromboembolism prophylaxis: Executive summary. Eur J Anaesthesiol. 2018 Feb; 35(2): 77 - 83.

64. Wormer K.C., Jangda A.A., El Sayed F.A., Stewart K.I., Mumford S.L., Segars J.H. Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis. Eur I Obstet Gynecol Reprod Biol. 2018 May; 224: 117 - 24.

65. Filipovic-Pierucci A., Gabet A., Deneux-Tharaux C., Plu-Bureau G., Arterial and venous complications after fertility treatment: A French nationwide cohort study. Eur J Obstet Gynecol Reprod Biol [Internet]. 2019 Jun; 237: 57 - 63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S030121151930106X

66. Villani M., Favuzzi G., Totaro P., Chinni E., Vecchione G., Vergura P., et al. Venous thromboembolism in assisted reproductive technologies: comparison between unsuccessful versus successful cycles in an Italian cohort. J Thromb Thrombolysis [Internet]. 2018 Feb 23; 45(2): 234 - 9. Available from: http://link.springer.com/10.1007/s11239-017-1584-z

67. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep; 53(3): 397 - 417.

68. Malbrain M., De Waele J. Intra-Abdominal Hypertension. Cambridge: Cambridge University Press; 2013.

69. Tso L.O., Costello M.F., Albuquerque LET, Andriolo R.B., Macedo C.R. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014 Nov; (11).

70. Al-Inany H.G., Youssef M.A., Ayeleke R.O., Brown J., Lam W.S., Broekmans F.J. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane database Syst Rev. 2016; 4: CD001750.

71. Lambalk C.B., Banga F.R., Huirne J.A., Toftager M., Pinborg A., Homburg R., et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017; 23(5): 560 - 79.

72. Lensen S.F., Wilkinson J., Leijdekkers J.A., La Marca A., Mol BWJ, Marjoribanks J., et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane database Syst Rev. 2018; 2: CD012693.

73. Engmann L., DiLuigi A., Schmidt D., Nulsen J., Maier D., Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective rando. Fertil Steril [Internet]. 2008; 89(1): 84 - 91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17462639

74. Melo M., Busso C.E., Bellver I., Alama P., Garrido N., Meseguer M., et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online. 2009 Oct; 19(4): 486 - 92.

75. Youssef MAFM, Van der Veen F., Al-Inany H.G., Mochtar M.H., Griesinger G., Nagi Mohesen M., et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane database Syst Rev [Internet]. 2014; (10): CD008046. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25358904

76. Leitao VMS, Moroni R.M., Seko LMD, Nastri C.O., Martins W.P. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril [Internet]. 2014; 101(3): 664 - 75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24360566

77. Kwan I., Bhattacharya S., Kang A., Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane database Syst Rev. 2014 Aug; (8): CD005289.

78. Smulders B., van Oirschot S.M., Farquhar C., Rombauts L., Kremer J.A. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane database Syst Rev. 2010 Jan; (1): CD006109.

79. Mochtar M.H., Van der Veen, Ziech M., van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane database Syst Rev. 2007 Apr; (2): CD005070.

80. Tan S-L, Balen A., Hussein E El, Campbell S., Jacobs H.S. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Fertil Steril [Internet]. 1992 Aug; 58(2): 378 - 83. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0015028216552236

81. Malbrain MLNG, Cheatham M.L., Kirkpatrick A., Sugrue M., Parr M., De Waele J., et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med. 2006 Nov; 32(11): 1722 - 32.

82. Burch J.M., Moore E.E., Moore F.A., Franciose R. The abdominal compartment syndrome. Surg Clin North Am. 1996 Aug; 76(4): 833 - 42.

83. Vlahos N.F., Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci. 2006 Dec; 1092: 247 - 64.